Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.5 to v3.6.6, signaling a new build of the page. It likely reflects minor fixes or updates to the page rather than changes to the study data.
    Difference
    0.0%
    Check dated 2026-09-01T18:20:04.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    A new line '2018 ( U.S. NIH Grant/Contract )' was added to the study's identifiers section. This records NIH funding information associated with the trial.
    Difference
    0.0%
    Check dated 2026-08-25T19:49:22.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The page now shows an updated revision label Revision: v3.6.5, and the Plain Language Summary section has been removed along with the older Revision: v3.6.4.
    Difference
    0.0%
    Check dated 2026-08-11T18:55:12.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.3 to v3.6.4, reflecting a minor update to the page's version metadata rather than its content.
    Difference
    0.0%
    Check dated 2026-07-21T12:52:26.000Z thumbnail image
  6. Check
    69 days ago
    Change Detected
    Summary
    - Revision: v3.6.3 is now shown, replacing v3.6.0, signaling a version update to the page's underlying system. This change updates metadata and does not alter the study details or core content.
    Difference
    0.0%
    Check dated 2026-06-30T02:36:14.000Z thumbnail image
  7. Check
    83 days ago
    Change Detected
    Summary
    Added recruitment status note and new user-help sections (How to Read a Study Record, Common Questions, How to Join a Study) and a revised Intervention/Treatment section; removed the older 'Intervention / Treatment' heading and the 'Revision: v3.5.5' note.
    Difference
    0.2%
    Check dated 2026-06-15T23:54:57.000Z thumbnail image

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.